CoChat

Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients

Open access
Chen, Jing‐Hua, Chu, Xiang‐Peng, Zhang, Jia‐Tao, Nie, Qiang, Tang, Wen‐Fang, Su, Jian, Yan, Hong‐Hong, Zheng, Hong‐Ping, Chen, Ze‐Xin, Chen, Xin, Song, Meng‐Meng, Yi, Xin, Li, Pan‐Song, Guan, Yan‐Fang, Li, Gang, Deng, Chu‐Xia, Rosell, Rafael, Wu, Yi‐Long, Zhong, Wen‐Zhao · 2020 · Thoracic Cancer
Cited by 75

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Background: Patient‐derived organoid (PDO) models are highly valuable and have potentially widespread clinical applications. However, limited information is available regarding organoid models of non‐small cell lung cancer (NSCLC). This study aimed to characterize the consistency between primary tumors in NSCLC and PDOs and to explore the applications of PDOs as preclinical models to understand and predict treatment response during lung cancer. Methods: Fresh tumor samples were harvested for organoid culture. Primary tumor samples and PDOs were analyzed via whole‐exome sequencing. Paired samples were subjected to immunohistochemical analysis. There were 26 antineoplastic drugs tested in the PDOs. Cell viability was assessed using the Cell Titer Glo assay 7–10 days after drug treatment. A heatmap of log‐transformed values of the half‐maximal inhibitory concentrations was generated on the basis of drug responses of PDOs through nonlinear regression (curve fit). A total of 12 patients (stages I–III) were enrolled, and 7 paired surgical tumors and PDOs were analyzed. Results: PDOs retained the histological and genetic characteristics of the primary tumors. The concordance between tumors and PDOs in mutations in the top 20 NSCLC‐related genes was >80% in five patients. Sample purity was significantly and positively associated with variant allele frequency (Pearson r = 0.82, P = 0.0005) and chromosome stability. The in vitro response to drug screening with PDOs revealed high correlation with the mutation profiles in the primary tumors. Conclusions: PDOs are highly credible models for detecting NSCLC and for prospective prediction of the treatment response for personalized precision medicine. Key points: Lung cancer organoid models could save precious time of drug testing on patients, and accurately select anticancer drugs according to the drug sensitivity results, so as to provide a powerful supplement and verification for the gene sequencing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1759-7714.13542

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 75

Metadata

Authors
Chen, J., Chu, X., Zhang, J., Nie, Q., Tang, W., Su, J., Yan, H., Zheng, H., Chen, Z., Chen, X., Song, M., Yi, X., Li, P., Guan, Y., Li, G., Deng, C., Rosell, R., Wu, Y., & Zhong, W.
Venue
Thoracic Cancer
Publisher
Wiley
Published
2020-07-07
Volume
11
Issue
8
Pages
2279-2290
ISSN
  • 1759-7706 (ISSN-L)
  • 1759-7714
OpenAlex
W3040790495
Cited by
75
References
22
FWCI
4.19
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients. https://app.cochat.ai/papers/10.1111/1759-7714.13542
The paper
Chen, J., Chu, X., Zhang, J., Nie, Q., Tang, W., Su, J., Yan, H., Zheng, H., Chen, Z., Chen, X., Song, M., Yi, X., Li, P., Guan, Y., Li, G., Deng, C., Rosell, R., Wu, Y., & Zhong, W. (2020). Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients. Thoracic Cancer. https://doi.org/10.1111/1759-7714.13542

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.